• The association between chronic kidney disease and bleeding is unknown.
• We followed 10 347 subjects at high cardiovascular risk for bleeding events.
• Chronic kidney disease was associated with a 1.5-fold increased bleeding risk.
• Especially albuminuria rather than decreased kidney function was associated with bleeding events.
Summary. Background: There are indications that patients with chronic kidney disease have an increased bleeding risk. Objectives: To investigate the association between chronic kidney disease and bleeding in patients at high cardiovascular risk. Methods: We included 10 347 subjects referred to the University Medical Center Utrecht (the Netherlands) from September 1996 to February 2015 for an outpatient visit with classic risk factors for arterial disease or with symptomatic arterial disease (Second Manifestation of Arterial disease [SMART] cohort).
Patients were staged according to the KDIGO guidelines, on the basis of estimated glomerular filtration rate (eGFR) and albuminuria, and were followed for the occurrence of major hemorrhagic events until March 2015. Hazard ratios (HRs) with 95% confidence intervals (CIs) for bleeding were calculated with Cox proportional hazards analyses. Results: The incidence rate for bleeding in subjects with chronic kidney disease was 8.0 per 1000 person-years and that for subjects without chronic kidney disease was 3.5 per 1000 person-years. Patients with chronic kidney disease (n = 2443) had a 1.5-fold (95% CI 1.2-1.9) increased risk of bleeding as compared with subjects without chronic kidney disease (n = 7904) after adjustment. Subjects with an eGFR of < 45 mL min À1 1.73 m -2 with albuminuria had a 3.5-fold (95% CI 2.3-5.3) increased bleeding risk, whereas an eGFR of < 45 mL min À1 1.73 m -2 without albuminuria
Introduction
Several studies have shown that patients with decreased kidney function or albuminuria have increased levels of procoagulant factors [1] [2] [3] . Furthermore, it has been shown that chronic kidney disease increases the risk of arterial [4, 5] and venous [6] [7] [8] thrombosis. Therefore, chronic kidney disease is considered to be a hypercoagulable state associated with a high prevalence of vascular diseases [9] . In contrast to the increased thrombosis risk, there are also several studies that have shown an increased bleeding risk in patients with chronic kidney disease [10] [11] [12] [13] [14] [15] [16] [17] . Frequent use of antithrombotic agents, a high rate of interventions and an intrinsic defect in platelets leading to platelet dysfunction are potential explanations for this increased bleeding risk in patients with chronic kidney disease [18] [19] [20] [21] .
The use of antithrombotic drugs should be weighed against the risk of bleeding in patients with chronic kidney disease. The bleeding risk in patients with chronic kidney disease and an increased risk of arterial disease or symptomatic arterial disease are matters of debate. In patients with chronic kidney disease and atrial fibrillation, there is uncertainty about the effectiveness and safety of vitamin K antagonists with regard to stroke and bleeding [22, 23] . To our knowledge, there are no studies investigating the bleeding risk related to chronic kidney disease, including both albuminuria and kidney function, in patients with an increased risk of arterial disease or with symptomatic arterial disease.
The aim of our study was to evaluate the relationship between chronic kidney disease stages and incident bleeding in patients at high cardiovascular risk with and without clinically manifest arterial disease in a large cohort.
Methods

Study population
The Second Manifestation of Arterial disease (SMART) study, a single-center prospective cohort study, included 10 347 patients aged 18-79 years, newly referred to the University Medical Center Utrecht (the Netherlands) for an outpatient visit with classic risk factors for arterial disease (hypertension, hyperlipidemia, and diabetes mellitus) or with symptomatic arterial disease (coronary artery disease, cerebrovascular disease, peripheral arterial obstructive disease, or abdominal aortic aneurysm). Patients underwent standardized vascular screening, including a health questionnaire and laboratory assessment, and were contacted twice yearly during the follow-up to fill in a questionnaire. Patients were included during the period September 1996 to February 2015, and then followed until March 2015. Patients were excluded if they had a terminal malignancy or if they were not sufficiently fluent in Dutch. A detailed description of the study has been published previously [24] .
Measurements
Creatinine was measured with enzymatic dry chemistry kits (Johnson and Johnson, New Brunswick, NJ, USA). Creatinine measurements were standardized to the reference method of isotope-dilution mass spectrometry. Albumin and creatinine levels were measured in a morning urine portion. Urinary creatinine was measured with dry chemistry kits (Johnson and Johnson) and albuminuria was determined with immunoturbidimetric assays (Boehringer-Mannheim, Mannheim, Germany). All assessments were performed at a single laboratory.
Chronic kidney disease
The glomerular filtration rate (GFR) was estimated by use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study equation [25] . In an additional analysis, the Modification of Diet in Renal Disease (MDRD) study equation [26] was used to estimate GFR instead of the CKD-EPI equation. The urine albumin/creatinine ratio was used to estimate albuminuria. An albumin/creatinine ratio of < 3 mg mmol À1 was considered to be normal, and an albumin/creatinine ratio of ≥ 3 mg mmol
À1
was regarded as albuminuria [27] . Chronic kidney disease was staged according to the KDIGO guidelines [27] .
Subjects with chronic kidney disease had either an estimated GFR (eGFR) of < 60 mL min À1 
Bleeding
The primary outcome was defined as the first occurrence of a fatal or non-fatal hemorrhagic event. This included any intracranial bleeding, fatal bleeding, and any bleeding complication requiring hospitalization. Bleeding events were confirmed by evaluation of hospital discharge records and the results of relevant laboratory and radiology examinations. Three members of the SMART committee independently audited all events on the basis of available information, and, in the case of disagreement, consensus was reached by consulting other members of the outcome committee.
Data analyses
Baseline characteristics of the participants were compared between subjects without chronic kidney disease and subjects with chronic kidney disease. Continuous data were reported as medians with interquartile ranges (IQRs).
Person-years of follow-up were counted from the date of inclusion to the date of a first bleeding event, death, or the end of the study period (March 2015), whichever came first. Subjects with incomplete follow-up were censored from the date of the last observation.
To investigate whether subjects with chronic kidney disease had an increased risk of (total, intracranial, and extracranial) bleeding, Cox proportional hazard regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) as compared with subjects without chronic kidney disease. The proportional hazards assumption was evaluated by use of a log-log plot, and formally tested by the use of Schoenfeld residuals. Furthermore, we calculated HRs with 95% CIs of bleeding for different chronic kidney disease stages as compared with subjects without chronic kidney disease. HRs were stepwise-adjusted in different models. In model 1, we adjusted for age and sex. In model 2, we additionally adjusted for body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, and diabetes mellitus. In model 3, we additionally adjusted for use of vitamin K antagonists and antiplatelet agents, and hemoglobin levels. Statistical interactions of chronic kidney disease with age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents and hemoglobin levels were tested.
In addition, we investigated the association between kidney function and bleeding. For this purpose, we calculated HRs with 95% CIs for subjects with an eGFR between 60 mL min À1 . HRs were adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, hemoglobin levels, and albuminuria categories.
We also calculated HRs with 95% CIs for subjects with a urine albumin/creatinine ratio between 3 mg mmol À1 and 30 mg mmol À1 and for subjects with a urine albumin/ creatinine ratio of > 30 mg mmol À1 as compared with subjects without albuminuria. HRs were adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, hemoglobin levels, and eGFR (continuous). The adjusted associations between eGFR as a continuous variable and bleeding, and between albuminuria as a continuous variable and bleeding, were assessed with plots of cubic splines by the use of R version 3.1.2.
In sensitivity analyses, we stratified the analyses for subjects who used vitamin K antagonists as antithrombotic treatment, for subjects who used antiplatelet agents as antithrombotic treatment, and for subjects who did not use vitamin K antagonists or antiplatelet agents. Furthermore, we repeated the same analyses by using the MDRD formula for staging chronic kidney disease instead of the CKD-EPI formula. Analyses were performed with SPSS version 23.0 (IBM SPSS Statistics, Chicago, IL, USA).
Results
Baseline characteristics
In total, 499 subjects withdrew their informed consent, leaving 10 347 subjects for the analyses. Of the 10 347 subjects, 2443 (24%) had chronic kidney disease defined as an eGFR of < 60 mL min À1 1.73 m À2 or albuminuria of ≥ 3 mg mmol À1 creatinine (Table 1) . Subjects with chronic kidney disease were older, were more often female, had a higher body mass index, more often had hypertension, more often had a history of stroke, myocardial infarction, or peripheral arterial disease, more often had diabetes mellitus, more often used antiplatelet agents or vitamin K antagonists and had lower hemoglobin levels than subjects without chronic kidney disease.
Chronic kidney disease is associated with an increased risk of bleeding
Overall, 350 subjects developed a first bleeding event during a median observation period of 7.2 years (IQR 3.6-11.0 years) and 625 subjects were lost to follow-up. An intracranial bleeding event was observed in 76 subjects, and 274 subjects had extracranial bleeding. Of the 274 subjects with extracranial bleeding, 18 subjects had rupture of an abdominal aneurysm, one subject had retinal bleeding, 83 subjects had intervention-related bleeding, and 172 subjects had other non-intervention-related bleeding. The incidence rate for bleeding in subjects with chronic kidney disease was 8.0 (95% CI 6.7-9.3) per 1000 person-years, and that for subjects without chronic kidney disease was 3.5 (95% CI 3.0-3.9) per 1000 person-years ( Table 2 ). The crude HR for the association between chronic kidney disease and bleeding was 2.3 (95% CI 1.9-2.8). Chronic kidney disease as compared with no chronic kidney disease was associated with a 1.5-fold (95% CI 1.2-1.9) increased bleeding risk adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, and hemoglobin levels. Regarding the relationship between chronic kidney disease and bleeding events, there were no statistical interactions for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, and hemoglobin levels. The incidence rates of intracranial bleeding were 1.8 (95% CI 1.1-2.4) per 1000 person-years in subjects with chronic kidney disease and 0.7 (95% CI 0.5-1.0) per 1000 person-years for subjects without chronic kidney disease. The incidence rate of extracranial bleeding in subjects with chronic kidney disease was 6.2 (95% CI 5.1-7.4) per 1000 person-years, and that in subjects with no chronic kidney disease was 2.7 (95% CI 2.3-3.1) per 1000 personyears. Chronic kidney disease as compared with no chronic kidney disease was associated with a 1.7-fold (95% CI 1.1-2.9) increased intracranial bleeding risk and with a 1.4-fold (95% CI 1.1-1.9) increased extracranial bleeding risk after full adjustment.
Chronic kidney disease stages and risk of bleeding (Table 3 ).
Albuminuria and risk of bleeding
Subjects with a urine albumin/creatinine ratio between 3 mg mmol À1 and 30 mg mmol À1 had a 1.9-fold (95% CI 1.5-2.5) increased bleeding risk and subjects with a urine albumin/creatinine ratio of > 30 mg mmol À1 had a 2.7-fold (95% CI 1.6-4.7) increased bleeding risk as compared with subjects without albuminuria after full adjustment including eGFR levels (Table 4) .
In subjects with an eGFR of < 60 mL min À1 1.73 m À2 , a urine albumin/creatinine ratio between 3 mg mmol À1 and 30 mg mmol À1 was associated with a 2.5-fold (95% CI 1.6-4.0) increased bleeding risk and a urine albumin/creatinine ratio of > 30 mg mmol À1 was associated with a 2.8-fold (95% CI 1.3-6.2) increased bleeding risk as compared with subjects without albuminuria after full adjustment. Analyses of albuminuria as a continuous variable confirmed that the risk of bleeding increased with the presence of albuminuria (Fig. 1) . Furthermore, the risk of bleeding increased below an eGFR of 45 mL min À1 1.73 m À2 (Fig. 2) .
Sensitivity analyses
Overall, 62% of the study subjects used antithrombotic therapy at baseline (54% used platelet inhibitors, 5% used oral anticoagulant therapy, and 3% used both in combination). Chronic kidney disease as compared with no chronic kidney disease was associated with a 1.3-fold (95% CI 0.7-2.5) increased bleeding risk for subjects who used vitamin K antagonists, a 1.6-fold (95% CI 1.2-2.2) increased bleeding risk for subjects who used antiplatelet agents, and a 1.5-fold (95% CI 1.0-2.4) increased bleeding risk for subjects who did not use vitamin K antagonists or antiplatelet agents after full adjustment. Analyses stratified on a history of stroke, myocardial infarction or peripheral arterial disease (41%) showed similar results. Chronic kidney disease was associated with a 1.7-fold (95% CI 1.2-2.5) increased bleeding risk in subjects without a history of stroke, myocardial infarction or peripheral arterial disease and with a 1.4-fold (95% CI 1.0-1.9) increased bleeding risk in subjects with a history of stroke, myocardial infarction or peripheral arterial disease after adjustment.
Results were also similar when the MDRD formula was used instead of the CKD-EPI formula to estimate GFRs. Chronic kidney disease, defined as an eGFR of < 60 mL min À1 1.73 m
À2
according to the MDRD ACR, urine albumin/creatinine ratio; CI, confidence interval; HR, hazard ratio. Model 1: HR adjusted for age and sex. Model 2: HR adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, and diabetes mellitus. Model 3: HR adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, hemoglobin levels, and estimated glomerular filtration rate (continuous).
formula or the presence of albuminuria, was associated with a 1.6-fold (95% CI 1.3-2.0) increased risk of bleeding after adjustment. The HRs of bleeding were 1.3 (95% CI 0.7-2.6) for subjects with an eGFR of < 45 mL min À1 1.73 m À2 according to the MDRD formula without albuminuria and 3.6 (95% CI 2.4-5.6) for subjects with an eGFR of < 45 mL min À1 1.73 m À2 with albuminuria as compared with subjects without chronic kidney disease adjusted for age, sex, body mass index, hypertension, history of stroke, history of myocardial infarction, history of peripheral arterial disease, diabetes mellitus, use of vitamin K antagonists and antiplatelet agents, and hemoglobin levels.
Discussion
In this large cohort study in patients at high cardiovascular risk, relationships were found between albuminuria and intracranial and extracranial bleeding. The highest bleeding risk was found for patients with an eGFR of < 45 mL min À1 1.73 m À2 with albuminuria (chronic kidney disease stage G3b-5A2/3), who had a 3.5-fold increased bleeding risk as compared with patients without chronic kidney disease. We found that patients with a urine albumin/creatinine ratio between 3 mg mmol À1 and 30 mg mmol À1 had a 1.9-fold increased bleeding risk and patients with a urine albumin/creatinine ratio of > 30 mg mmol À1 had a 2.7-fold increased bleeding risk as compared with patients without albuminuria. Patients with an eGFR of < 60 mL min À1 1.73 m À2 without albuminuria did not have an increased risk of bleeding as compared with patients without chronic kidney disease.
Our data are in line with those from the limited studies on chronic kidney disease and bleeding risk. A previous study investigated the effect of albuminuria and kidney function on major bleeding events, including intracranial and extracranial bleeding, in the general population [11] . In that study, both albuminuria and eGFR were found to be associated with an increased bleeding risk. Furthermore, the investigators showed that patients with albuminuria (> 30 mg mmol À1 ) and an eGFR between 15 mL min À1 with albuminuria in our study. However, in the previous study, bleeding events were not confirmed by hospital discharge records or by the results of relevant laboratory and radiology examinations. Furthermore, information on hemoglobin levels and the use of antiplatelet agents and anticoagulation medication use in subjects aged < 65 years, which are potential confounders or mediators in the relationship between chronic kidney disease and bleeding, were not included in the analysis.
Other previous studies focused on bleeding events in dialysis patients [10, [12] [13] [14] [15] [16] [17] . Most of these studies showed increased gastrointestinal bleeding rates, ranging from 21 to 161 per 1000 person-years, in dialysis patients [14] [15] [16] [17] . In addition, several studies showed increased bleeding rates, ranging from 45 to 177 per 1000 person-years, associated with vitamin K antagonist use in dialysis patients with atrial fibrillation [28] [29] [30] . Only limited studies have investigated the association between hemorrhagic stroke and chronic kidney disease [31, 32] . These studies showed a 1.2-2.9-fold increased risk of hemorrhagic stroke in subjects with albuminuria. Our finding that chronic kidney disease is associated with a 1.7-fold increased intracranial bleeding risk and a 1.4-fold increased extracranial bleeding risk is in line with these studies [10] [11] [12] [13] [14] [15] [16] [17] 28, 29, 31, 32] .
The results of the present study indicate a more important role for albuminuria than for decreased kidney function as a risk factor for bleeding in patients with earlier stages of chronic kidney disease. These findings are in line with several other studies in the general population suggesting a higher risk for subjects with chronic kidney disease in the presence of albuminuria than for subjects with chronic kidney disease in the absence of albuminuria for different adverse outcomes, such as cardiovascular disease and the development of end-stage renal disease [4, 5, 33] . Albuminuria reflecting endothelial damage is probably a better marker for disease activity than mildly or moderately decreased kidney function, especially in the early stages of chronic kidney disease. However, severely decreased eGFR levels are probably associated with an increased risk of bleeding, as can be seen in our cubic spline analysis. The association of chronic kidney disease in the presence of albuminuria with both thrombotic events and bleeding events might be explained by treatment-related issues, by a differential effect on distinct hemostasis pathways, and by vascular vulnerability related to chronic kidney disease. Subjects with chronic kidney disease have, in general, a high prevalence of vascular comorbidities and, as a consequence, frequent use of antiplatelet agents and anticoagulants, which may contribute to the increased bleeding risk. In the present study, the use of antithrombotic and anticoagulant agents was high, but did not explain the relationship between chronic kidney disease and bleeding risk. Risk estimates for chronic kidney disease as compared with no chronic kidney disease were in the same direction when stratified for vitamin K antagonist use, for antiplatelet agent use, and for patients who did not use antiplatelet agents and vitamin K antagonists. Furthermore, kidney disease has been associated with platelet dysfunction, especially in patients with end-stage renal disease, which could be another mechanism involved in the association between chronic kidney disease and bleeding [20, 21] . Finally, chronic kidney disease in the presence of albuminuria may reflect endothelial dysfunction and the presence of a frail vascular system that is prone to both bleeding and thrombosis.
The major strength of this study was the use of a large clinical cohort study located in the Netherlands with information on kidney function, albuminuria and bleeding. This study has also several limitations. First, the KDIGO guidelines require impaired GFR or albuminuria for at least 3 months. As in most studies, repeated measurements for a period of at least 3 months were not available in our study, and some subjects may therefore have been falsely classified as having chronic kidney disease. Second, the study population comprised patients with or at high risk of cardiovascular disease. Therefore, the results of the study cannot be generalized to all patients. Third, as in daily clinical practice in most patients and in most other studies, albuminuria was measured by the use of spot urine samples rather than a 24-h urine collection. Fourth, we used intracranial bleeding, fatal bleeding and any bleeding complication requiring hospitalization as the bleeding outcome instead of the ISTH criteria for major bleeding (fatal bleeding, symptomatic bleeding in a critical area or organ, or bleeding causing a fall in hemoglobin level of 2 g dL À1 [1.24 mM]), and we had no data on the severity of bleeding. Fifth, we had no information on prior bleeding, which could be a confounder in the relationship between chronic kidney disease and bleeding events. Finally, we had no information on the initiation or cessation of the use of vitamin K antagonists and antiplatelet agents during follow-up. Clinicians should be aware of the increased risk of bleeding in patients with early stages of chronic kidney disease in the presence of albuminuria. There has been a recent debate on the effectiveness of vitamin K antagonist in subjects with chronic kidney disease and atrial fibrillation [23, 29, 30] . Vitamin K antagonist use has been associated with accelerated vascular calcification resulting from the inhibition of matrix Gla protein in patients with and without chronic kidney disease [34] , and with increased stroke and mortality risks [22, 35] . Therefore, with a probable decreased effectiveness of vitamin K antagonists in preventing stroke resulting from vascular calcification, an increased bleeding risk becomes more relevant in subjects with chronic kidney disease than in subjects without chronic kidney disease. Severely decreased kidney function has already been included in several bleeding risk scores, such as the HAS-BLED (creatinine levels of > 200 lM) [36] , ATRIA (eGFR of < 30 mL min À1 ) [37] and HEMORR 2 HAGES (creatinine levels of > 221 lM) [38] risk scores. Our current data suggest that albuminuria might be a more important predictor than eGFR levels. Therefore, future studies on bleeding risk prediction models should take albuminuria into account. Furthermore, clinical trials are needed to investigate the effectiveness of antithrombotic therapy in patients with chronic kidney disease, taking into account increased bleeding risks. In summary, we have shown that chronic kidney disease in the presence of albuminuria is an independent risk factor for bleeding in patients with classic risk factors for arterial disease or with symptomatic arterial disease. Visseren drafted the manuscript. All authors were involved in data interpretation, and all authors revised the manuscript for important intellectual content.
